Stockscreener 앱 받기
15.55
2.37%
0.36
시간 외 거래:
15.47
-0.08
-0.51%
전일 마감가:
$15.19
열려 있는:
$15.01
하루 거래량:
40,387
Relative Volume:
0.25
시가총액:
$140.67M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-777.50
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
+7.69%
1개월 성능:
-6.66%
6개월 성능:
+31.00%
1년 성능:
-14.24%
1일 변동 폭
$15.01
$16.03
1주일 범위
$14.50
$16.03
52주 변동 폭
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.55 | 137.42M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Why Seres Therapeutics Inc. stock is in analyst buy zone2026 world cup usa national team qualification defensive leaders high defensive line winner prediction insights - Улправда
Seres Therapeutics expands board, appoints new director - MSN
Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com India
Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent
Will Seres Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Report & Safe Entry Point Identification - DonanımHaber
Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber
Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда
Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда
Seres Therapeutics Cuts Costs to Extend Cash Runway - MSN
Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) - Defense World
North America Human Microbiome Market - MarketsandMarkets
Guidance Update: How Seres Therapeutics Inc 1S90 stock compares with market leaders2025 Biggest Moves & Long-Term Growth Stock Strategies - moha.gov.vn
Published on: 2025-12-13 20:57:20 - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN
Seres Therapeutics, Inc. (MCRB) 5.04% in After-hours: What’s Driving the Move? - Stocks Telegraph
Seres Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened - Defense World
Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42 - Nasdaq
What risks investors should watch in Seres Therapeutics Inc. stockQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc. (1S90) stock outperform foreign stocksWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Will Seres Therapeutics Inc. (1S90) stock beat value stocks2025 Year in Review & Verified Chart Pattern Signals - Newser
What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Seres Therapeutics Inc. stock dividend yield sustainablePortfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Seres Therapeutics Inc. stock positioned for long term growth2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Seres Therapeutics (MCRB) Stock Analysis Report | Financials & Insights - Benzinga
Volatility Watch: Why Seres Therapeutics Inc. stock is rated strong buyJuly 2025 Review & High Accuracy Trade Alerts - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
A look into Seres Therapeutics Inc (MCRB)’s deeper side - Setenews
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Seres Therapeutics Inc Stock Analysis and ForecastHead and Shoulders Patterns & Big Gains Low Cost - earlytimes.in
What analysts say about Seres Therapeutics Inc stockMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Should You Watch Rane Engine Valve Limited for Sector Rotation UpsideWeekly Market Snapshot & Free Stock Market Mentorship Programs - earlytimes.in
Can Poonawalla Fincorp Limited Deliver Consistent Free Cash FlowsMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
Seres Therapeutics, Inc. (MCRB) -17.5% in Normal Trading: Shares Dip Amid Recent Insider Sales - Stocks Telegraph
How reliable is Seres Therapeutics Inc. (1S90) stock dividend growth2025 Support & Resistance & Safe Swing Trade Setups - newser.com
Will Seres Therapeutics Inc. (1S90) stock extend growth storyEarnings Trend Report & Daily Market Momentum Tracking - newser.com
Is Seres Therapeutics Inc. stock a top pick in earnings season - newser.com
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):